Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Company restores access to multiple sclerosis drug after pressure from neurologists.
Volumetric comparisons of supratentorial white matter hyperintensities on FLAIR MRI in patients with migraine and multiple sclerosis.
Tip variant focal segmental glomerulosclerosis associated with interferon-β treatment of multiple sclerosis.
Copolymer-1 induces adaptive immune anti-inflammatory glial and neuroprotective responses in a murine model of HIV-1 encephalitis.
Oral treatment with laquinimod augments regulatory T-cells and brain-derived neurotrophic factor expression and reduces injury in the CNS of mice with experimental autoimmune encephalomyelitis.
Predictive value of early brain atrophy on response in patients treated with interferon β.
Cytokine switch and bystander suppression of autoimmune responses to multiple antigens in experimental autoimmune encephalomyelitis by a single recombinant T-cell receptor ligand.
Chemistry, toxicology, pharmacology and pharmacokinetics of idebenone: a review.
First patient treated in Mapi Pharma's Phase IIa clinical trial of GA Depot for relapsing remitting multiple sclerosis (RRMS)
Rituximab Use in Pediatric Central Demyelinating Disease.
UPDATE 1-Teva Pharmaceutical banks on thrice-weekly Copaxone
Polymorphisms in the receptor tyrosine kinase MERTK gene are associated with multiple sclerosis susceptibility.
PI(3,5)P2 biosynthesis regulates oligodendrocyte differentiation by intrinsic and extrinsic mechanisms.
Analysis: Healthy babies born after accelerated elimination of teriflunomide
Neuroprotective effect of masitinib in rats with postischemic stroke.
FTY720 in patients with primary progressive multiple sclerosis (INFORMS)
Treatment of neuromyelitis optica.
Roche's new time-saving subcutaneous formulation of MabThera approved in Europe for the treatment of common forms of non-Hodgkin Lymphoma
Takeda Submits a New Drug Application for Glatiramer Acetate in Japan for the Relapse Prevention of Multiple Sclerosis
New data analyses show significant clinical and MRI improvements with PLEGRIDY™ (peginterferon beta-1a)
Laquinimod in multiple sclerosis.
First proof for rituximab in IgG4-related disease
Long-Term Cost-Effectiveness Model of Interferon Beta-1b in the Early Treatment of Multiple Sclerosis in the United States.
Varicella-Zoster Virus Infections in Patients Treated With Fingolimod: Risk Assessment and Consensus Recommendations for Management.
Oral Laquinimod for Multiple Sclerosis Granted Fast Track Status by FDA

Pages